What is the appropriate dose and frequency of bupropion XL (extended‑release) for an elderly patient with an estimated glomerular filtration rate of 59 mL/min/1.73 m² who has anxiety?

Bupropion XL Dosing in Elderly Patient with eGFR 59 and Anxiety

For an elderly patient with eGFR 59 mL/min/1.73 m² and anxiety, bupropion XL 150 mg daily should be reduced to 150 mg every other day, and alternative agents such as SSRIs (escitalopram, sertraline) or buspirone should be strongly considered as first-line therapy given the anxiety presentation.

Renal Dosing Considerations

The FDA label explicitly states that bupropion XL requires dose reduction in renal impairment (eGFR <90 mL/min) because bupropion and its metabolites are cleared renally and accumulate to a greater extent than usual 1. With an eGFR of 59 mL/min (Stage 3 CKD), this patient has moderate renal impairment requiring adjustment.

Specific dosing recommendation:

• Reduce from 150 mg daily to 150 mg every other day 1
• Monitor closely for adverse reactions indicating drug or metabolite accumulation
• Elderly patients are at particular risk given age-related decline in renal function 1

Research supports this conservative approach: a pharmacokinetic study in hemodialysis patients demonstrated significant accumulation of hydroxybupropion and threohydrobupropion metabolites, suggesting 150 mg every 3 days for severe renal impairment 2. Your patient's eGFR of 59 warrants an intermediate reduction to every-other-day dosing.

Anxiety-Specific Concerns

Bupropion is problematic for anxiety disorders and should be reconsidered in this patient:

• Bupropion is activating and explicitly noted to "should not be used in agitated patients" 3
• While recent evidence suggests bupropion may reduce anxiety symptoms in patients with comorbid depression and mild-to-moderate anxiety 4, 5, 6, it can also provoke anxiety, particularly at higher doses 5
• The stimulating properties (increased norepinephrine and dopamine) can worsen anxiety symptoms 5

Preferred Alternatives for Elderly Patients with Anxiety

Better medication choices for this clinical scenario:

First-Line Options:

• Escitalopram 10 mg daily (well-tolerated, preferred in elderly) 7
• Sertraline 25-50 mg daily (less drug interactions than other SSRIs) 3, 7
• Buspirone 5 mg twice daily (specifically for anxiety, titrate to 20 mg three times daily maximum) 3

If Depression is Primary with Comorbid Anxiety:

• Citalopram 10 mg daily (well-tolerated, maximum 40 mg) 3
• Mirtazapine 7.5 mg at bedtime (if insomnia present, promotes sleep) 3

Clinical Algorithm

Decision pathway:

1. Is anxiety the primary or prominent symptom?

   • Yes → Choose SSRI (escitalopram/sertraline) or buspirone
   • No, depression predominates → Consider continuing bupropion with dose adjustment

2. If continuing bupropion XL:

   • Reduce to 150 mg every other day (not daily)
   • Monitor for insomnia, agitation, tremor, anxiety worsening
   • Reassess at 2-4 weeks; if anxiety worsens, switch to SSRI
   • Check renal function periodically as elderly patients' eGFR may decline further 1

3. Monitor for metabolite accumulation signs:

   • Seizure risk (bupropion lowers seizure threshold) 8, 9
   • Insomnia (give dose in morning, not after 3 PM) 3
   • Tremor, agitation, confusion

Critical Pitfalls to Avoid

• Do not continue 150 mg daily dosing with eGFR 59—this risks metabolite accumulation and toxicity 1, 2
• Do not ignore the anxiety component—bupropion's activating properties may worsen anxiety 3, 5
• Do not assume normal renal function based on serum creatinine alone in elderly patients; always calculate eGFR 10
• Avoid combining with other serotonergic agents if switching to SSRI (allow washout period) 7

Elderly-Specific Considerations

Pharmacokinetic studies show elderly patients have approximately 80% of the bupropion clearance seen in younger patients, with mean half-life of 34 hours (vs. 21 hours in younger adults) 11. Metabolites accumulate disproportionately with repeated dosing in the elderly 11. The FDA label confirms no overall safety differences were observed in elderly patients, but emphasizes that renal function decline necessitates dose adjustment 1.

The combination of elderly age + moderate renal impairment + anxiety presentation makes bupropion a suboptimal choice. Switching to an SSRI would address both the anxiety and avoid the renal dosing complexity, with escitalopram or sertraline being preferred agents in this population 7.